Gilead 1Q Revenues: $5.3 billion (+4%) 1Q Earnings: $2.0 billion (+28%) Comments: HIV product sales were $3.6 billion, up 13% primarily driven by higher sales as a result of the continued uptake of Biktarvy. Chronic hepatitis C virus (HCV) product sales were $790 million down 21% primarily due to lower patient starts and competitive dynamics, including a decline in price in U.S. Medicare. Yescarta, which was approved in the U.S. in October 2017 and Europe in August 2018, generated $96 million...